288. 自己免疫性後天性凝固因子欠乏症 Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details

臨床試験数 : 205 / 薬物数 : 238 - (DrugBank : 31) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 26

5 trials found

diseases per page:

Showing 1 to 5 of 5 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04344860 (ClinicalTrials.gov)	June 4, 2021	9/4/2020	Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial	Prospective, Randomized Trial Comparing Recombinant Von Willebrand Factor (rVWF) Plus Tranexamic Aci ...	Von Willebrand Diseases;Postpartum Hemorrhage	Drug: Recombinant Von Willebrand factor;Drug: Tranexamic Acid Injection [Cyklokapron]	Margaret Ragni	NULL	Recruiting	18 Years	N/A	Female	20	Phase 3	United States
2	NCT04146376 (ClinicalTrials.gov)	October 12, 2019	29/10/2019	Von Willebrand Factor in Pregnancy (VIP) Study	Von Willebrand Factor in Pregnancy (VIP) Study: A Multicenter Study of Wilate Use in Von Willebrand ...	Von Willebrand Diseases	Other: Use of a postpartum diary and additional blood draws;Drug: VWF replacement therapy with Wilat ...	Bloodworks	Mary M. Gooley Hemophilia Center;Ergomed;Octapharma	Recruiting	18 Years	N/A	Female	110		United States
3	NCT02606045 (ClinicalTrials.gov)	February 7, 2019	5/11/2015	Minimize Menorrhagia in Women With Von Willebrand Disease	Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tran ...	Von Willebrand Diseases	Drug: recombinant von Willebrand factor;Drug: tranexamic acid	Margaret Ragni	University of North Carolina;Duke University	Active, not recruiting	13 Years	45 Years	Female	60	Phase 3	United States
4	NCT01800435 (ClinicalTrials.gov)	October 2011	15/2/2013	A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acidin Haemophilia A Patie ...	Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agent ...	Hereditary Factor VIII Deficiency Disease With Inhibitor	Drug: aPCC, aPCC + TXA;Drug: rFVIIa , rFVIIa + TXA	Oslo University Hospital	NULL	Completed	18 Years	65 Years	Male	6	Phase 4	Norway
5	NCT00111215 (ClinicalTrials.gov)	January 2001	18/5/2005	Treatment and Management of Women With Bleeding Disorders	Treatment and Management of Women With Bleeding Disorders	Menorrhagia;Blood Coagulation Disorders;Blood Platelet Disorders;Von Willebrand Disease;Hematologic ...	Drug: Tranexamic Acid;Drug: Desmopressin Acetate	Centers for Disease Control and Prevention	NULL	Completed	18 Years	50 Years	Female	100	N/A	United States

First Previous1Next Last